Customize KDTA Antibody

Description

Clarifying "KDTA Antibody": Potential Misinterpretation

The term "KDTA" does not correspond to a recognized antibody in the provided sources. Instead, kdtA refers to a bacterial gene encoding 3-deoxy-D-manno-octulosonic acid (Kdo) transferase, an enzyme critical for lipid A biosynthesis in Gram-negative bacteria. Antibodies targeting bacterial components related to kdtA are discussed in the context of pathogen studies (see Section 2).

Role of kdtA in Bacterial Pathogenesis and Antibody Studies

The kdtA gene is essential for synthesizing lipopolysaccharide (LPS), a key component of the bacterial outer membrane. Mutations in kdtA disrupt LPS assembly, impairing bacterial viability and virulence.

**Key Findings from kdtA-Related Antibody Research**

Study Focus	Key Observations	Source
Lipopolysaccharide Biosynthesis	kdtA mutants accumulate lipid IVA (LPS precursor) and exhibit growth defects. Antibodies against kdtA-complemented LPS show cross-reactivity with Chlamydia antigens.
Francisella novicida Pathogenesis	ΔkdtA mutants are attenuated in mice, with reduced survival and slower growth. Antibodies against kdtA mutants may aid in vaccine development.

Antibody Characterization in Bacterial and Therapeutic Contexts

While no "KDTA Antibody" exists, the following antibody-related research highlights methodologies and applications relevant to bacterial targets:

Antibody Affinity and Kinetics

Antibodies targeting bacterial antigens (e.g., VEGFR2 in cancer therapy) are characterized by their equilibrium dissociation constant ( $K_D$ ), association rate ( $k_{on}$ ), and dissociation rate ( $k_{off}$ ). For example:

Antibody	$k_{on}$ (M⁻¹s⁻¹)	$k_{off}$ (s⁻¹)	$K_D$ (nM)
KD035	2.67	5.78	0.22
B1	2.98	53.9	1.81

Source: KD035 (a therapeutic antibody) shows higher affinity ( $K_D = 0.22 \, \text{nM}$ ) than its precursor B1 ( $K_D = 1.81 \, \text{nM}$ ) .

Anti-Kidd Antibodies in Transfusion Medicine

Antibodies against Kidd blood group antigens (Jk⁰, Jk³) are implicated in delayed hemolytic transfusion reactions (DHTRs) and hemolytic disease of the newborn (HDN). Key characteristics:

Prevalence: Anti-Jk³ is rare but linked to severe DHTRs.
Severity: HDN caused by anti-Kidd antibodies is typically mild.
Source: Kidd antigens are critical for urea transport in red blood cells and kidneys .

Anti-Drug Antibody (ADA) Analysis

ADAs (e.g., neutralizing or non-neutralizing antibodies against therapeutic proteins) are monitored in clinical trials. Key metrics include:

ADA Type	Impact on Drug Function	Detection Methods
Neutralizing	Blocks drug activity, reduces efficacy	Competitive ELISA, functional assays
Non-Neutralizing	Alters drug PK/PD, may cause hypersensitivity	Screening/confirmation assays

Source: ADA analysis requires standardized protocols for titer measurement and PK/PD modeling .

Future Directions and Challenges

Bacterial Vaccine Development: kdtA mutants may serve as attenuated vaccine candidates, with antibodies against LPS aiding in pathogen neutralization.
Antibody Validation: Use of knockout (KO) cell lines or CRISPR-edited models improves antibody specificity testing (e.g., KD035’s binding to VEGFR2 was validated via X-ray crystallography and mutagenesis ).
Data Standardization: Initiatives like the Antibody Society’s product database aim to streamline antibody characterization for therapeutic applications .

Product Specs

Buffer

**Preservative:** 0.03% Proclin 300
**Constituents:** 50% Glycerol, 0.01M PBS, pH 7.4

Form

Liquid

Lead Time

Made-to-order (14-16 weeks)

Synonyms

KDTA antibody; At5g03770 antibody; F17C15.190 antibody; MED24.5 antibody; Probable 3-deoxy-D-manno-octulosonic acid transferase antibody; mitochondrial antibody; AtKdtA antibody; Kdo transferase A antibody; EC 2.4.99.12 antibody; EC 2.4.99.13 antibody; Bifunctional Kdo transferase antibody; Kdo-lipid IV(A) 3-deoxy-D-manno-octulosonic acid transferase antibody; Lipid IV(A) 3-deoxy-D-manno-octulosonic acid transferase antibody

Target Names

KDTA

Uniprot No.

Q8VZA5

Target Background

Function

KDTA plays a crucial role in the biosynthesis of lipid A, a phosphorylated glycolipid essential for bacterial cell membrane integrity. Specifically, it catalyzes the transfer of two 3-deoxy-D-manno-octulosonate (Kdo) residues from CMP-Kdo to lipid IV(A). Lipid IV(A) is a tetraacyldisaccharide-1,4'-bisphosphate precursor of lipid A, which anchors the lipopolysaccharide to the outer membrane of bacteria. Interestingly, lipid A-like molecules have been observed in plants and are thought to serve as structural components of mitochondrial and chloroplast outer membranes. Additionally, they may participate in signal transduction or plant defense responses.

Gene References Into Functions

The AtKDTA gene encodes a putative Kdo transferase (KDTA) involved in the synthesis of a yet-to-be-identified mitochondrial lipid A-like molecule. This suggests that AtKDTA is not involved in the synthesis of the cell wall RG-II. [AtKDTA] PMID: 20124190

Database Links

KEGG: ath:AT5G03770

STRING: 3702.AT5G03770.1

UniGene: At.28587

Protein Families

Glycosyltransferase group 1 family, Glycosyltransferase 30 subfamily

Subcellular Location

Mitochondrion.

Tissue Specificity

Expressed in leaves, stems and flowers.

Q&A

Here’s a structured collection of research-focused FAQs for KDTA Antibody, designed for academic investigators and prioritizing methodological rigor:

Advanced Research Questions

What strategies resolve contradictory binding data between SPR and cell-based assays?
- Investigate post-translational modifications (e.g., glycosylation) in native cell membranes versus recombinant proteins. Use glycoengineering (e.g., HEK293 GnTI⁻ cells) to isolate structural variables .
How to design a robust in vivo efficacy study for KDTA Antibody in murine models?
- Employ syngeneic tumors with confirmed target expression (IHC ≥2+ H-score) and randomize into:
  
  Group Dose (mg/kg) Frequency Endpoint
  1 5 Q7D×4 Tumor volume (mm³)
  2 10 Q7D×4 Metastasis count
  Control – – –
- Include PD analyses (e.g., phospho-target ELISA) .
What computational approaches predict off-target interactions of KDTA Antibody?
- Perform homology modeling (Rosetta, AlphaFold) of the paratope-epitope interface. Cross-reference with Protein Data Bank (PDB) using BLASTp (E-value ≤1e⁻⁵) to flag structural homologs .

Group	Dose (mg/kg)	Frequency	Endpoint
1	5	Q7D×4	Tumor volume (mm³)
2	10	Q7D×4	Metastasis count
Control	–	–	–

Data Analysis & Technical Challenges

How to address batch-to-batch variability in KDTA Antibody production?
- Implement high-resolution LC-MS for post-purification sequence verification. Monitor critical quality attributes (CQAs):
  
  CQA Target Range
  Aggregation ≤5% (SEC-HPLC)
  Endotoxin <1 EU/mg
  Binding affinity $K_D$ ±15%
- Use design-of-experiments (DoE) for process optimization .
What orthogonal assays confirm target engagement in complex biological matrices?
- Combine proximity ligation assays (PLA) with NanoBRET for real-time quantification in live cells. Validate using isogenic target-positive/-negative lines .

CQA	Target Range
Aggregation	≤5% (SEC-HPLC)
Endotoxin	<1 EU/mg
Binding affinity	$K_D$ ±15%

Experimental Design Considerations

How to statistically power studies evaluating KDTA Antibody’s therapeutic window?
- For 80% power (α=0.05), calculate sample size using historical variance data:
  $n = \frac{2(Z_{\alpha/2} + Z_\beta)^2 \sigma^2}{\Delta^2}$
  Where $Δ$ = minimum detectable effect size, $σ$ = standard deviation .

Quick Inquiry

Personal Email Detected

Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *

Name*

Email*

Phone

Country

Source

Quantity&Size*

Product Name

Message

KDTA Antibody